SUMMARY A double-blind cross-over study of 35 out-patients with rheumatoid arthritis showed that Naproxen and Indomethacin suppositories were both effective forms of treatment in rheumatoid arthritis, both being significantly superior to placebo in terms of relief of morning stiffness.
Indomethacin is a drug used widely in rheumatological practice. The oral dose employed is variable, but previous studies have suggested that one 100 mg suppository is as effective as 100 mg of capsules in relief of early morning stiffness in the treatment of rheumatoid arthritis.
More recently Naproxen tablets have been introduced as an analgesic, anti-inflammatory compound in the treatment of rheumatoid arthritis. At a dose of 500 mg it has been suggested that, of the available proprionic acid derivatives, it is a drug of choice judged by patient preference. It produced the least number of unwanted effects compared with other drugs of this group (Huskisson et al., 1976) .
The results of a comparative trial between Indomethacin, Naproxen, and placebo suppositories are reported.
Material and methods

TRIAL DESIGN
Out-patients with rheumatoid arthritis were admitted to the trial at both King's College Hospital, London and Wrightington Hospital, Lancashire. The trial was three-way, double-blind, and of crossover design. The suppositories contained Naproxen 500 mg or Indomethacin 100 mg or inactive placebo. The trial period was 3 weeks on each treatment. The suppositories were all the same colour and the placebo suppositories matched the Indomethacin suppositories; the Naproxen suppositories whilst they were of the same colour and design were slightly larger. Treatment was allocated randomly using all 6 possible orders of administration. During the trial, patients were allowed up to 3 g per day of Paracetamol as an escape drug. All other nonsteroidal anti-inflammatory drugs were stopped 1 Accepted for publication December 5, 1977 week before the start of the trial. Patients on stabilised dosage of penicillamine, gold, or corticosteroids were included in the study.
The efficacy of treatment was assessed initially and then at the end of each trial period by means of: (1) Pain using the 10 cm visual analogue scale, range 'no pain' to 'worst ever pain' (Berry and Huskisson, 1972) . (2) Early morning stiffness recorded in minutes. (3) Articular index using the method of Ritchie et al. (1968) . (4) Ring size of the proximal interphalangeal joints. (5) Patient preference for the 3 treatments. (6) Doctor preference for the 3 treatments. (7) Blood levels were also measured in order to ascertain the absorption of Naproxen.
UNWANTED EFFECTS These were elicited in 3 different groups. Proctoscopy: the results of this were recorded as normal, ulceration, erosion, oedema, erythema, or bleeding. Rectal symptoms were elicited by asking whether the patient had had any rectal problems. Different side effects were elicited by means of simple indirect question, 'Has the treatment upset you in any way ?'.
Results
A total of 35 patients were admitted to the study, 11 male and, 24 female. All had erosive rheumatoid arthritis and 29 of the patients were sero-positive, 13 patients received no other therapy, 11 were taking penicillamine, 9 gold salts and 4 corticosteroids.
CLINICAL RESULTS
Pain measured on a 10 cm visual analogue scale was reduced by all 3 treatments. For Naproxen and Indomethacin the change was statistically significant at the P<0 05 level. Both active Indomethacin and Naproxen suppositories in the treatment of rheumatoid arthritis 371 suppositories were superior to placebo. This reached significance in favour of Indomethacin (P < 0.05) but not Naproxen. There was no statistical difference between the active drugs.
Morning stiffness was significantly reduced by Naproxen (P <0 .03) and by Indomethacin (P < 0-01) but not by placebo. Both Naproxen and Indomethacin were significantly better than placebo in reducing morning stiffness (P < 0 05). Improvement in articular index was seen with both drugs but not with placebo. However, only the change on Indomethacin was significantly superior to placebo (P < 0 02).
The difference between the active preparations was not significant. Ring size was reduced by all 3 treatments with no difference between their effects. (Table 1 ).
BLOOD LEVELS
Blood was taken from 29 patients for assessment of Naproxen levels. One patient showed no demonstrable Naproxen in his blood (he showed preference for placebo at the end of the trial!). The range of levels was from 5-2 to 78-6 Fg/ml of Naproxen. The mean was 32 7 ,ug/ml.
BOWEL HABIT
No change occurred during the study either in the frequency of bowel action or stool formation on any treatment. There was marked discrepancy between the two centres in terms of the number of side effects reported (many more at Wrightington than at King's), but the actual number ofpatients developing side effects was similar.
WITHDRAWALS
Four patients discontinued therapy during the course of the study. Three had pain during the placebo period and the third had an unrelated admission to hospital.
PATIENT AND OBSERVER PREFERENCE
The physicians favoured Indomethacin (14 times), Naproxen (12 times), and placebo (5 times). The patients' preference was for Indomethacin (12), Naproxen (11), placebo (6), and no difference twice. There was no significant difference between these results. 
